


**From:** Thompson, Edward  
**Sent:** Tuesday, May 19, 2015 11:20 AM  
**To:** Kevin Darryl (KD) White (Kevin.White@cslbehring.com)  
**Cc:** Monica.Richardson@cslbehring.com  
**Subject:** Mid-Cycle Communication Document for BL 125582/0

Dear Erik,

Please find attached the Mid-Cycle Communication memo for our conference scheduled for May 22, 2015 at 11 a.m.



The list of participants is found in the memo.

Sincerely,  
Ed

Edward Thompson  
Regulatory Project Manager  
FDA/CBER  
Office of Blood Research and Review  
(240) 402-8443  
email: [edward.thompson@fda.hhs.gov](mailto:edward.thompson@fda.hhs.gov)  
10903 New Hampshire Avenue  
WO71-4212  
Silver Spring, MD 20993-0002

## Mid-Cycle Communication

**Application type:** Original BLA

**Tracking number:** STN 125582/0

**Product name:** Coagulation Factor IX (Recombinant), Albumin Fusion Protein

**Proposed Indication:** To treat patients with hemophilia B (congenital Factor IX deficiency) for (1) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes; (2) Control and prevention of bleeding episodes; and (3) Control and prevention of bleeding in perioperative setting

**Applicant:** CSL Behring Recombinant Facility AG

**Meeting date & time:** 22 May 2015, Friday at 11:00 AM

**Committee Chair:** Mikhail Ovanesov, PhD

**RPM:** Edward Thompson

**CBER Review Team Attendees:**

Mikhail Ovanesov, PhD, CBER/OBRR/DHRR/LH  
Edward Thompson, RPM, CBER/OBRR

**Other Attendees:**

Christopher Sese, Independent Assessor, Eastern Research Group  
Kimberly Taylor, CDER/OPI/OPA/PES

**Discussion Summary:**

1. No significant issues or major deficiencies have been identified by the review committee to date.
2. The review of the clinical data to date did not raise major safety concerns. The current thinking of the review committee is that a *Risk Evaluation and Mitigation Strategy* (REMS) is not required.
3. With regard to risk management, routine pharmacovigilance is recommended.
4. The current thinking of the review committee is that this BLA will not be presented at the *Blood Products Advisory Committee* meeting.

5. Information requests (IRs) sent but responses from CSL Behring have not been received:
  - FDA sent two IRs about Endotoxin assay methods on 04 May 2015 and 11 May 2015, and is expecting CSL Behring's response by 22 May 2015.
  - FDA sent an additional IR about validation of analytical methods for Factor IX Activity, (b) (4), Purity and Residual Water Content on 07 May 2015, and is expecting CSL Behring's response by 01 June 2015.
6. FDA will send CSL Behring another IR on the characterization of the albumin moiety by (b) (4) in May 2015. Please note that the review is ongoing and additional information may be requested as the need arises.
7. The following facility is currently scheduled for a pre-license inspection on 27 May 2015 to 4 June 2015: CSL Behring GmbH, FEI: 3003098680, DUNS: 326530474; Address: Emil-von-Behring-Str. 76, D-35041 Marburg, Germany.
8. The late-cycle face-to-face meeting is scheduled on 25 August 2015, Tuesday from 1:30 p.m. to 3:30 p.m.
9. The action due date for this submission is Friday, 04 December 2015.

End

Application Number: BLA 125582/0

Document Type: Mid-Cycle Communication Teleconference Agenda

History:      Drafted:      Edward Thompson/May 13, 2015  
                 Revisions:      Mikhail Ovanesov/May 18, 2015  
                 Revisions:      Tim Lee/May 18, 2015